Trial Profile
A prospective ,observational study to evaluate the efficacy and safety of tetrahydrocannabinol/cannabidiol oromucosal spray in Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Feb 2021
Price :
$35
*
At a glance
- Drugs Nabiximols (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 29 Sep 2016 New trial record